Literature DB >> 15284859

Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.

C Kelaidi1, F Rollot, S Park, M Tulliez, B Christoforov, Y Calmus, P Podevin, D Bouscary, P Sogni, P Blanche, F Dreyfus.   

Abstract

A link between chronic hepatitis C virus (HCV) infection and low-grade B-cell lymphomas has been suggested by epidemiological studies. Marginal zone lymphomas (MZLs) including splenic lymphomas with villous lymphocytes are among the most frequently reported subgroups in the setting of chronic HCV infection. In this study, we examined the effect of antiviral treatment in eight patients with HCV-associated MZL. We found that five out of eight patients have responded to interferon alpha and ribavirin. In some cases, hematologic responses were correlated to virologic responses. In addition, we report a case of large granular lymphocyte leukemia occurring in association with MZL and HCV, and responding to interferon and ribavirin. We suggest that there is an etiologic link between HCV and antigen-driven lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15284859     DOI: 10.1038/sj.leu.2403443

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  27 in total

1.  HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution.

Authors:  Souichi Shiratori; Yutaka Tsutsumi; Takahito Kawamura; Kazuhiro Kudo; Norihiko Shimoyama; Nobuo Masauzi; Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2008-03-06       Impact factor: 2.490

Review 2.  Hepatitis C as a systemic disease: virus and host immunologic responses underlie hepatic and extrahepatic manifestations.

Authors:  Chiaki Okuse; Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

3.  Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.

Authors:  Luca Arcaini; Davide Rossi
Journal:  Haematologica       Date:  2012-05       Impact factor: 9.941

4.  Risk of malignant lymphoma following viral hepatitis infection.

Authors:  Pierluigi Cocco; Giovanna Piras; Maria Monne; Antonella Uras; Attilio Gabbas; Maria G Ennas; Angelo Palmas; Marco Murineddu; Stefania Collu; Massimo Melis; Marco Rais; Pierfelice Todde; Maria G Cabras; Emanuele Angelucci; Giovannino Massarelli; Alexandra Nieters
Journal:  Int J Hematol       Date:  2008-05-01       Impact factor: 2.490

Review 5.  Non-Hodgkin lymphoma and hepatitis C: where we are and what next?

Authors:  Mihály Sulyok; Mihály Makara; Eszter Újhelyi; István Vályi-Nagy
Journal:  Pathol Oncol Res       Date:  2014-10-02       Impact factor: 3.201

Review 6.  Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?

Authors:  Barbara Vannata; Luca Arcaini; Emanuele Zucca
Journal:  Ther Adv Hematol       Date:  2015-12-29

Review 7.  Extrahepatic manifestations of chronic hepatitis C virus infection.

Authors:  Patrice Cacoub; Cloe Comarmond; Fanny Domont; Léa Savey; Anne C Desbois; David Saadoun
Journal:  Ther Adv Infect Dis       Date:  2016-02

8.  Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.

Authors:  Monika Joshi; Hassan Sheikh; Kamal Abbi; Sarah Long; Kamal Sharma; Mark Tulchinsky; Elliot Epner
Journal:  Ther Adv Hematol       Date:  2012-10

9.  Hepatitis C virus infection and locally advanced splenic marginal zone lymphoma.

Authors:  Bartlomiej Szynglarewicz; Rafał Matkowski; Zbigniew Smorag; Jozef Forgacz; Marek Pudelko; Jan Kornafel
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

10.  Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia.

Authors:  Edgar D Charles; Rashidah M Green; Svetlana Marukian; Andrew H Talal; Gerond V Lake-Bakaar; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.